vs

Side-by-side financial comparison of Kearny Financial Corp. (KRNY) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Kearny Financial Corp. is the larger business by last-quarter revenue ($44.3M vs $35.5M, roughly 1.2× RECURSION PHARMACEUTICALS, INC.). Kearny Financial Corp. runs the higher net margin — 22.9% vs -304.2%, a 327.1% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 14.8%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 9.3%).

Kearny Financial Corp. is a U.S.-based bank holding company operating Kearny Bank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, mortgages, business loans, and wealth management services, primarily serving customers across New Jersey and the New York metropolitan region.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

KRNY vs RXRX — Head-to-Head

Bigger by revenue
KRNY
KRNY
1.2× larger
KRNY
$44.3M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+667.0% gap
RXRX
681.7%
14.8%
KRNY
Higher net margin
KRNY
KRNY
327.1% more per $
KRNY
22.9%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
9.3%
KRNY

Income Statement — Q1 FY2027 vs Q4 FY2025

Metric
KRNY
KRNY
RXRX
RXRX
Revenue
$44.3M
$35.5M
Net Profit
$10.1M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
22.9%
-304.2%
Revenue YoY
14.8%
681.7%
Net Profit YoY
7.3%
39.6%
EPS (diluted)
$0.16
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KRNY
KRNY
RXRX
RXRX
Q1 27
$44.3M
Q1 26
$44.3M
Q4 25
$43.5M
$35.5M
Q3 25
$43.6M
$5.2M
Q2 25
$40.8M
$19.2M
Q1 25
$38.6M
$14.7M
Q4 24
$37.5M
$4.5M
Q3 24
$37.1M
$26.1M
Net Profit
KRNY
KRNY
RXRX
RXRX
Q1 27
$10.1M
Q1 26
$10.1M
Q4 25
$9.4M
$-108.1M
Q3 25
$9.5M
$-162.3M
Q2 25
$6.8M
$-171.9M
Q1 25
$6.6M
$-202.5M
Q4 24
$6.6M
$-178.9M
Q3 24
$6.1M
$-95.8M
Gross Margin
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Operating Margin
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
27.1%
-304.8%
Q3 25
27.5%
-3327.6%
Q2 25
20.0%
-916.8%
Q1 25
20.3%
-1297.9%
Q4 24
20.9%
-4042.4%
Q3 24
19.4%
-377.1%
Net Margin
KRNY
KRNY
RXRX
RXRX
Q1 27
22.9%
Q1 26
22.9%
Q4 25
21.7%
-304.2%
Q3 25
21.8%
-3135.3%
Q2 25
16.6%
-894.2%
Q1 25
17.2%
-1373.3%
Q4 24
17.5%
-3935.5%
Q3 24
16.4%
-367.5%
EPS (diluted)
KRNY
KRNY
RXRX
RXRX
Q1 27
$0.16
Q1 26
$0.16
Q4 25
$0.15
$-0.17
Q3 25
$0.15
$-0.36
Q2 25
$0.11
$-0.41
Q1 25
$0.11
$-0.50
Q4 24
$0.10
$-0.56
Q3 24
$0.10
$-0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KRNY
KRNY
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$123.8M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$763.0M
$1.1B
Total Assets
$7.6B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KRNY
KRNY
RXRX
RXRX
Q1 27
$123.8M
Q1 26
$123.8M
Q4 25
$147.3M
$743.3M
Q3 25
$130.1M
$659.8M
Q2 25
$167.3M
$525.1M
Q1 25
$126.1M
$500.5M
Q4 24
$141.6M
$594.4M
Q3 24
$155.6M
$427.6M
Total Debt
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Stockholders' Equity
KRNY
KRNY
RXRX
RXRX
Q1 27
$763.0M
Q1 26
$763.0M
Q4 25
$757.4M
$1.1B
Q3 25
$753.2M
$1.0B
Q2 25
$746.0M
$919.1M
Q1 25
$748.1M
$933.9M
Q4 24
$744.9M
$1.0B
Q3 24
$751.5M
$524.6M
Total Assets
KRNY
KRNY
RXRX
RXRX
Q1 27
$7.6B
Q1 26
$7.6B
Q4 25
$7.6B
$1.5B
Q3 25
$7.6B
$1.4B
Q2 25
$7.7B
$1.3B
Q1 25
$7.7B
$1.3B
Q4 24
$7.7B
$1.4B
Q3 24
$7.8B
$726.5M
Debt / Equity
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KRNY
KRNY
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
$14.3M
$-46.1M
Q3 25
$1.5M
$-117.4M
Q2 25
$24.8M
$-76.4M
Q1 25
$16.8M
$-132.0M
Q4 24
$-2.7M
$-115.4M
Q3 24
$2.5M
$-59.2M
Free Cash Flow
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$21.4M
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
FCF Margin
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
52.4%
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Capex Intensity
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
3.5%
Q3 25
4.7%
Q2 25
8.3%
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Cash Conversion
KRNY
KRNY
RXRX
RXRX
Q1 27
Q1 26
Q4 25
1.51×
Q3 25
0.16×
Q2 25
3.66×
Q1 25
2.53×
Q4 24
-0.40×
Q3 24
0.42×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons